[go: up one dir, main page]

AU2001266604A1 - Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders - Google Patents

Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders

Info

Publication number
AU2001266604A1
AU2001266604A1 AU2001266604A AU6660401A AU2001266604A1 AU 2001266604 A1 AU2001266604 A1 AU 2001266604A1 AU 2001266604 A AU2001266604 A AU 2001266604A AU 6660401 A AU6660401 A AU 6660401A AU 2001266604 A1 AU2001266604 A1 AU 2001266604A1
Authority
AU
Australia
Prior art keywords
rank ligand
treatment
monoclonal antibodies
mediated disorders
antibodies useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266604A
Inventor
Simon M. Blake
Raymond W. Sweet
Alexander H. Taylor
Trevor A. Wattam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of AU2001266604A1 publication Critical patent/AU2001266604A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001266604A 2000-05-26 2001-05-24 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders Abandoned AU2001266604A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20762800P 2000-05-26 2000-05-26
US60207628 2000-05-26
PCT/US2001/016865 WO2001091793A1 (en) 2000-05-26 2001-05-24 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders

Publications (1)

Publication Number Publication Date
AU2001266604A1 true AU2001266604A1 (en) 2001-12-11

Family

ID=22771340

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266604A Abandoned AU2001266604A1 (en) 2000-05-26 2001-05-24 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders

Country Status (6)

Country Link
US (1) US20030215450A1 (en)
EP (1) EP1283721A4 (en)
JP (1) JP2003534022A (en)
AU (1) AU2001266604A1 (en)
HK (1) HK1054316A1 (en)
WO (1) WO2001091793A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
DE60129254T2 (en) 2000-09-22 2008-03-13 Immunex Corp., Thousand Oaks SCREENING PROCESS FOR AGONISTS AND ANTAGONISTS OF THE RECEPTOR ACTIVATOR OF NF-KAPPA B
JP2005515752A (en) * 2001-05-18 2005-06-02 スミスクライン・ビーチャム・コーポレイション Anti-RANK ligand monoclonal antibodies useful in the treatment of RANK ligand-mediated disorders
US20040213788A1 (en) * 2001-05-18 2004-10-28 Sweet Raymond W. Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ES2706902T3 (en) 2001-06-26 2019-04-01 Amgen Inc Antibodies for OPGL
US7935338B2 (en) 2001-12-11 2011-05-03 University Of Massachusetts Antibodies to treat cancer
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005077462A2 (en) * 2004-02-09 2005-08-25 The Cbr Institute For Biomedical Research, Inc. Cd70 inhibition for the treatment and prevention of inflammatory bowel disease
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2009105934A1 (en) * 2008-02-27 2009-09-03 上海先导药业有限公司 Monoclonal antibody anti-human rankl
BRPI0822447A2 (en) 2008-03-14 2015-06-16 Biocon Ltd Monoclonal antibody and method thereof
CN102741286B (en) * 2010-03-26 2013-12-25 刘庆法 Anti human RANKL monoclonal antibodies developed by PAE technology and uses thereof
EP2953634B1 (en) 2013-02-07 2021-05-26 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
ES2962885T3 (en) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Tumor necrosis factor receptor superfamily antagonist antibodies
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation TYPE II ANTI-RECEPTOR AGONISTIC ANTIBODIES OF TUMOR NECROSIS FACTOR
CN116715767A (en) 2016-05-13 2023-09-08 综合医院公司 Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus
MX2019004862A (en) * 2016-10-28 2019-08-12 Lilly Co Eli Anti-rankl antibodies and uses thereof.
CN120227454B (en) * 2025-06-03 2025-09-02 深圳泰华赛尔生物科技有限公司 Application of stem cell exosome in preparation of medicines for preventing and treating bone joint diseases of pets

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
ATE419355T1 (en) * 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
CU22584A1 (en) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOCLONAL ANTIBODY THAT RECOGNIZES THE CD6 HUMAN LEUKOCYTARY DIFFERENTIATION ANTIGEN AND ITS USES FOR THE DIAGNOSIS AND TREATMENT OF PSORIASIS
WO1998028424A2 (en) * 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
WO1999029865A2 (en) * 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
IL141588A0 (en) * 1998-09-15 2002-03-10 M & E Biotech As Method for down-regulating osteoprotegerin ligand activity

Also Published As

Publication number Publication date
WO2001091793A1 (en) 2001-12-06
EP1283721A4 (en) 2004-07-07
US20030215450A1 (en) 2003-11-20
JP2003534022A (en) 2003-11-18
EP1283721A1 (en) 2003-02-19
HK1054316A1 (en) 2003-11-28

Similar Documents

Publication Publication Date Title
AU2001266604A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001288342A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
EP1482972A4 (en) Treatment of immunological disorders using anti-cd30 antibodies
EP2940044B8 (en) Anti-tnf alpha antibodies for use in therapy
TWI365193B (en) Human antibodies that bind human il-12 and methods for producing
PL398596A1 (en) Preparation containing human antibodies for the treatment of disorders associated with TNF-α
HUE064610T2 (en) Novel anti-il 13 antibodies and uses thereof
AU5441000A (en) Human monoclonal antibody
AU2002351374A8 (en) Antibodies to treat cancer
AU2001239510A1 (en) Treatment of renal disorders
EP1389233A4 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2002316162A1 (en) Method of increasing anti-neugc antibody levels in blood
AU2002309645A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001281099A1 (en) Production of human monoclonal antibodies
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2002320072A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
AU2002238858A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
WO2001092331A8 (en) Compositions and methods for the treatment of immune related diseases
AU2002316887A1 (en) Anti-ige antibody to treat ocular allergies
HK1045699A (en) Human antibodies that bind human il-12 and methods for producing
GB0024673D0 (en) Therapeutic antibodies
IL135025A0 (en) Monoclonal antibodies to the human ldl receptor, their production and use